Form 4: CytomX Therapeutics General Counsel Lloyd Rowland Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Lloyd Rowland, General Counsel of CytomX Therapeutics, sold 5,268 shares of common stock on March 19, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 19, 2024, Lloyd Rowland, the General Counsel of CytomX Therapeutics, sold 5,268 shares of the company's common stock.
- The sale was executed at a price of $2.0855 per share.
- This transaction was conducted to satisfy tax or other government withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Rowland directly owns 117,728 shares, which includes 52,916 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations. It doesn't indicate a positive or negative outlook for the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small percentage of the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of stock sale transaction. |
| 03/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.